Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial (2021)
Attributed to:
Developing efficient perpetual platform trials to study multiple treatments and multiple biomarkers
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s13063-021-05190-z
PubMed Identifier: 33845867
Publication URI: http://europepmc.org/abstract/MED/33845867
Type: Journal Article/Review
Parent Publication: Trials
Issue: 1
ISSN: 1745-6215